Standard Chemical & Pharmaceutical Co Ltd (1720) - Net Assets
Based on the latest financial reports, Standard Chemical & Pharmaceutical Co Ltd (1720) has net assets worth NT$9.02 Billion TWD (≈ $284.22 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$11.62 Billion ≈ $366.20 Million USD) and total liabilities (NT$2.60 Billion ≈ $81.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Standard Chemical & Pharmaceutical Co Lt liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$9.02 Billion |
| % of Total Assets | 77.61% |
| Annual Growth Rate | 8.23% |
| 5-Year Change | 82.97% |
| 10-Year Change | 130.93% |
| Growth Volatility | 9.4 |
Standard Chemical & Pharmaceutical Co Ltd - Net Assets Trend (2002–2024)
This chart illustrates how Standard Chemical & Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Standard Chemical & Pharmaceutical Co Lt asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Standard Chemical & Pharmaceutical Co Ltd (2002–2024)
The table below shows the annual net assets of Standard Chemical & Pharmaceutical Co Ltd from 2002 to 2024. For live valuation and market cap data, see Standard Chemical & Pharmaceutical Co Lt market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$8.98 Billion ≈ $282.80 Million |
+10.31% |
| 2023-12-31 | NT$8.14 Billion ≈ $256.37 Million |
+9.44% |
| 2022-12-31 | NT$7.44 Billion ≈ $234.26 Million |
+9.35% |
| 2021-12-31 | NT$6.80 Billion ≈ $214.23 Million |
+38.60% |
| 2020-12-31 | NT$4.91 Billion ≈ $154.56 Million |
+5.58% |
| 2019-12-31 | NT$4.65 Billion ≈ $146.39 Million |
+9.42% |
| 2018-12-31 | NT$4.25 Billion ≈ $133.78 Million |
+1.05% |
| 2017-12-31 | NT$4.20 Billion ≈ $132.39 Million |
+0.13% |
| 2016-12-31 | NT$4.20 Billion ≈ $132.22 Million |
+7.97% |
| 2015-12-31 | NT$3.89 Billion ≈ $122.46 Million |
+7.80% |
| 2014-12-31 | NT$3.61 Billion ≈ $113.60 Million |
+0.65% |
| 2013-12-31 | NT$3.58 Billion ≈ $112.87 Million |
+8.35% |
| 2012-12-31 | NT$3.31 Billion ≈ $104.17 Million |
+5.91% |
| 2011-12-31 | NT$3.12 Billion ≈ $98.36 Million |
+7.13% |
| 2010-12-31 | NT$2.91 Billion ≈ $91.81 Million |
+3.74% |
| 2009-12-31 | NT$2.81 Billion ≈ $88.50 Million |
+7.84% |
| 2008-12-31 | NT$2.60 Billion ≈ $82.07 Million |
+1.02% |
| 2007-12-31 | NT$2.58 Billion ≈ $81.23 Million |
+0.09% |
| 2006-12-31 | NT$2.58 Billion ≈ $81.17 Million |
+6.67% |
| 2005-12-31 | NT$2.42 Billion ≈ $76.09 Million |
+34.28% |
| 2004-12-31 | NT$1.80 Billion ≈ $56.67 Million |
+8.54% |
| 2003-12-31 | NT$1.66 Billion ≈ $52.21 Million |
+5.11% |
| 2002-12-31 | NT$1.58 Billion ≈ $49.67 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Standard Chemical & Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2225.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$3.71 Billion | 62.82% |
| Common Stock | NT$1.79 Billion | 30.26% |
| Other Comprehensive Income | NT$108.13 Million | 1.83% |
| Other Components | NT$300.13 Million | 5.08% |
| Total Equity | NT$5.91 Billion | 100.00% |
Standard Chemical & Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Standard Chemical & Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bus Online Co Ltd
SHE:002188
|
$344.15 Million |
|
TrueLight
TWO:3234
|
$344.18 Million |
|
NEWRON PHARMACEUT. EO-20
F:NP5
|
$344.21 Million |
|
Y.U.D. Yangtze River Investment Industry Co Ltd
SHG:600119
|
$344.22 Million |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
$343.99 Million |
|
Good Finance Securities Co Ltd
TWO:6021
|
$343.98 Million |
|
G-Tech Optoelectronics Corp
TW:3149
|
$343.91 Million |
|
China Western Power Industrial Co Ltd
SHE:002630
|
$343.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Standard Chemical & Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,299,016,000 to 5,905,015,000, a change of 605,999,000 (11.4%).
- Net income of 880,501,000 contributed positively to equity growth.
- Dividend payments of 482,479,000 reduced retained earnings.
- Other comprehensive income increased equity by 94,953,999.
- Other factors increased equity by 113,023,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$880.50 Million | +14.91% |
| Dividends Paid | NT$482.48 Million | -8.17% |
| Other Comprehensive Income | NT$94.95 Million | +1.61% |
| Other Changes | NT$113.02 Million | +1.91% |
| Total Change | NT$- | 11.44% |
Book Value vs Market Value Analysis
This analysis compares Standard Chemical & Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.18x to 1.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | NT$14.63 | NT$61.10 | x |
| 2007-12-31 | NT$14.72 | NT$61.10 | x |
| 2008-12-31 | NT$14.87 | NT$61.10 | x |
| 2009-12-31 | NT$15.81 | NT$61.10 | x |
| 2010-12-31 | NT$15.16 | NT$61.10 | x |
| 2011-12-31 | NT$16.21 | NT$61.10 | x |
| 2012-12-31 | NT$16.82 | NT$61.10 | x |
| 2013-12-31 | NT$18.58 | NT$61.10 | x |
| 2014-12-31 | NT$18.48 | NT$61.10 | x |
| 2015-12-31 | NT$19.82 | NT$61.10 | x |
| 2016-12-31 | NT$20.79 | NT$61.10 | x |
| 2017-12-31 | NT$20.53 | NT$61.10 | x |
| 2018-12-31 | NT$20.58 | NT$61.10 | x |
| 2019-12-31 | NT$21.05 | NT$61.10 | x |
| 2020-12-31 | NT$22.17 | NT$61.10 | x |
| 2021-12-31 | NT$24.27 | NT$61.10 | x |
| 2022-12-31 | NT$26.57 | NT$61.10 | x |
| 2023-12-31 | NT$29.62 | NT$61.10 | x |
| 2024-12-31 | NT$33.01 | NT$61.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Standard Chemical & Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.91%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.97%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 1.89x
- Recent ROE (14.91%) is above the historical average (11.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 9.37% | 11.38% | 0.46x | 1.81x | NT$-9.89 Million |
| 2003 | 10.32% | 12.92% | 0.40x | 1.98x | NT$5.32 Million |
| 2004 | 11.30% | 13.41% | 0.45x | 1.89x | NT$23.36 Million |
| 2006 | 13.30% | 16.81% | 0.55x | 1.43x | NT$80.33 Million |
| 2007 | 10.92% | 13.31% | 0.61x | 1.35x | NT$22.57 Million |
| 2008 | 11.05% | 12.58% | 0.62x | 1.43x | NT$26.17 Million |
| 2009 | 10.94% | 12.85% | 0.59x | 1.43x | NT$25.24 Million |
| 2010 | 7.78% | 7.26% | 0.64x | 1.67x | NT$-59.77 Million |
| 2011 | 8.50% | 7.41% | 0.68x | 1.68x | NT$-43.46 Million |
| 2012 | 9.03% | 8.05% | 0.66x | 1.70x | NT$-29.07 Million |
| 2013 | 9.07% | 9.77% | 0.57x | 1.63x | NT$-30.74 Million |
| 2014 | 11.32% | 11.36% | 0.61x | 1.63x | NT$43.78 Million |
| 2015 | 9.81% | 10.47% | 0.57x | 1.63x | NT$-6.57 Million |
| 2016 | 9.15% | 9.26% | 0.59x | 1.67x | NT$-31.72 Million |
| 2017 | 9.89% | 9.44% | 0.60x | 1.74x | NT$-3.96 Million |
| 2018 | 10.17% | 10.48% | 0.55x | 1.75x | NT$6.24 Million |
| 2019 | 10.00% | 9.56% | 0.57x | 1.84x | NT$60.80K |
| 2020 | 13.22% | 12.17% | 0.61x | 1.78x | NT$127.58 Million |
| 2021 | 16.28% | 15.35% | 0.46x | 2.33x | NT$272.55 Million |
| 2022 | 24.27% | 19.72% | 0.53x | 2.31x | NT$678.30 Million |
| 2023 | 15.76% | 13.38% | 0.56x | 2.11x | NT$304.98 Million |
| 2024 | 14.91% | 12.97% | 0.61x | 1.89x | NT$290.00 Million |
Industry Comparison
This section compares Standard Chemical & Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,620,907,222
- Average return on equity (ROE) among peers: 7.69%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Standard Chemical & Pharmaceutical Co Ltd (1720) | NT$9.02 Billion | 9.37% | 0.29x | $343.99 Million |
| Grape King Bio Ltd (1707) | $11.14 Billion | 19.47% | 0.35x | $527.39 Million |
| Maywufa Co Ltd (1731) | $1.67 Billion | 3.46% | 0.69x | $90.87 Million |
| ScinoPharm Taiwan Ltd (1789) | $3.44 Billion | 25.35% | 0.67x | $493.27 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $596.05 Million | -6.44% | 0.88x | $1.96 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $954.50 Million | -2.89% | 0.05x | $49.05 Million |
| LIWANLI Innovation Co Ltd (3054) | $520.52 Million | 6.31% | 1.40x | $178.88 Million |
| YungShin Global Holding Corp (3705) | $5.01 Billion | 14.43% | 0.38x | $464.08 Million |
| TTY Biopharm Co Ltd (4105) | $7.51 Billion | 19.30% | 0.45x | $590.67 Million |
| Phytohealth Corp (4108) | $1.75 Billion | -9.76% | 0.07x | $75.72 Million |
About Standard Chemical & Pharmaceutical Co Ltd
Standard Chemical & Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceutical products in Taiwan and internationally. The company offers Chinese and western medicine, cosmetics, beverage, normal instruments, and medical instruments. It also sells various medical supplements, as well as preventive medicine; and imports and exports various medical products, med… Read more